This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The objective of the study was to determine the clinical and economic impact of real-time polymerase chain reaction (PCR) detection of methicillin-resistant Staphylococcus aureus (MRSA) on hospital costs and transmission in comparison with standard MRSA screening in Canada.
Interventions
Real-time PCR for the detection of MRSA was compared with standard MRSA screening, which involved a selective broth enrichment culture method. The key difference between the two strategies was the turn-around time, which was far shorter with the real-time PCR approach.
Location/setting
Canada/hospital.
Methods

Analytical approach:
The economic evaluation used data from a local hospital to determine the accuracy and clinical consequences of the diagnostic strategies, while a decision tree model was developed to compare the costs of the two options. The time horizon of the analysis appears to have been restricted to the admission period. The authors did not state explicitly which perspective was adopted.
Effectiveness data:
The clinical data were derived from records of patients admitted to a large local hospital where the new diagnostic approach was introduced in November 2004. Thus, clinical data 6 months before and 6 months after the implementation of the new real-time PCR approach were compared. Standard MRSA screening with culture was used as the 'gold' standard against which the accuracy of the new approach was tested. The main outcome measure was the incidence of nosocomial MRSA colonisation or infection due to transmission. A time series analysis was performed to assess the effect of using real-time PCR screening on the rate of nosocomial MRSA colonisation or infection.
Monetary benefit and utility valuations:
None.
Measure of benefit:
The key clinical end point was the mean monthly incidence of nosocomial MRSA colonisation or infection. It was not
